Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals (NASDAQ:CNTA) had its price target raised by analysts at Truist Financial Corporation from $33.00 to $38.00. They now have a "buy" rating on the stock.
Centessa Pharmaceuticals (NASDAQ:CNTA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting [Yahoo! Finance]
Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting